Intrinsic value of Neos Therapeutics, Inc. - NEOS

Previous Close

$1.17

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$1.17

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of NEOS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  40
  62
  92
  134
  189
  260
  349
  458
  590
  745
  925
  1,131
  1,363
  1,622
  1,907
  2,219
  2,556
  2,918
  3,305
  3,716
  4,150
  4,607
  5,087
  5,589
  6,114
  6,661
  7,231
  7,824
  8,440
  9,081
Variable operating expenses, $m
  373
  576
  861
  1,248
  1,760
  2,419
  3,247
  4,263
  5,485
  6,928
  8,601
  10,515
  12,674
  15,080
  17,732
  20,626
  23,759
  27,127
  30,722
  34,541
  38,578
  42,828
  47,290
  51,959
  56,837
  61,923
  67,219
  72,730
  78,460
  84,416
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  373
  576
  861
  1,248
  1,760
  2,419
  3,247
  4,263
  5,485
  6,928
  8,601
  10,515
  12,674
  15,080
  17,732
  20,626
  23,759
  27,127
  30,722
  34,541
  38,578
  42,828
  47,290
  51,959
  56,837
  61,923
  67,219
  72,730
  78,460
  84,416
Operating income, $m
  -333
  -514
  -768
  -1,114
  -1,571
  -2,159
  -2,898
  -3,805
  -4,895
  -6,183
  -7,676
  -9,384
  -11,311
  -13,458
  -15,824
  -18,407
  -21,204
  -24,209
  -27,418
  -30,825
  -34,428
  -38,221
  -42,202
  -46,370
  -50,723
  -55,261
  -59,988
  -64,906
  -70,020
  -75,335
EBITDA, $m
  -329
  -508
  -759
  -1,102
  -1,554
  -2,137
  -2,869
  -3,767
  -4,847
  -6,122
  -7,602
  -9,294
  -11,202
  -13,329
  -15,672
  -18,230
  -21,000
  -23,976
  -27,154
  -30,529
  -34,097
  -37,854
  -41,797
  -45,924
  -50,235
  -54,730
  -59,412
  -64,282
  -69,347
  -74,611
Interest expense (income), $m
  3
  10
  15
  26
  41
  63
  91
  127
  172
  228
  295
  374
  465
  570
  688
  820
  965
  1,124
  1,295
  1,480
  1,676
  1,886
  2,107
  2,339
  2,584
  2,839
  3,106
  3,385
  3,675
  3,976
  4,290
Earnings before tax, $m
  -343
  -529
  -794
  -1,155
  -1,634
  -2,250
  -3,025
  -3,977
  -5,123
  -6,477
  -8,049
  -9,849
  -11,881
  -14,146
  -16,644
  -19,372
  -22,327
  -25,504
  -28,897
  -32,502
  -36,313
  -40,328
  -44,542
  -48,953
  -53,562
  -58,368
  -63,373
  -68,581
  -73,996
  -79,625
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -343
  -529
  -794
  -1,155
  -1,634
  -2,250
  -3,025
  -3,977
  -5,123
  -6,477
  -8,049
  -9,849
  -11,881
  -14,146
  -16,644
  -19,372
  -22,327
  -25,504
  -28,897
  -32,502
  -36,313
  -40,328
  -44,542
  -48,953
  -53,562
  -58,368
  -63,373
  -68,581
  -73,996
  -79,625

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  138
  213
  319
  462
  652
  897
  1,204
  1,581
  2,034
  2,569
  3,190
  3,901
  4,701
  5,594
  6,577
  7,651
  8,813
  10,062
  11,396
  12,813
  14,310
  15,887
  17,542
  19,274
  21,083
  22,970
  24,934
  26,979
  29,104
  31,313
Adjusted assets (=assets-cash), $m
  138
  213
  319
  462
  652
  897
  1,204
  1,581
  2,034
  2,569
  3,190
  3,901
  4,701
  5,594
  6,577
  7,651
  8,813
  10,062
  11,396
  12,813
  14,310
  15,887
  17,542
  19,274
  21,083
  22,970
  24,934
  26,979
  29,104
  31,313
Revenue / Adjusted assets
  0.290
  0.291
  0.288
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
Average production assets, $m
  26
  40
  60
  87
  122
  168
  226
  296
  381
  481
  598
  731
  881
  1,048
  1,232
  1,433
  1,651
  1,885
  2,135
  2,400
  2,681
  2,976
  3,286
  3,611
  3,950
  4,303
  4,671
  5,054
  5,452
  5,866
Working capital, $m
  -5
  -8
  -13
  -18
  -26
  -36
  -48
  -63
  -81
  -102
  -127
  -155
  -187
  -222
  -261
  -304
  -350
  -400
  -453
  -509
  -569
  -631
  -697
  -766
  -838
  -913
  -991
  -1,072
  -1,156
  -1,244
Total debt, $m
  90
  157
  252
  382
  553
  773
  1,049
  1,388
  1,796
  2,278
  2,837
  3,476
  4,197
  5,000
  5,885
  6,852
  7,898
  9,022
  10,222
  11,497
  12,845
  14,264
  15,753
  17,312
  18,940
  20,638
  22,407
  24,246
  26,159
  28,148
Total liabilities, $m
  124
  192
  287
  416
  587
  807
  1,084
  1,423
  1,831
  2,312
  2,871
  3,511
  4,231
  5,034
  5,920
  6,886
  7,932
  9,056
  10,257
  11,531
  12,879
  14,298
  15,788
  17,346
  18,975
  20,673
  22,441
  24,281
  26,194
  28,182
Total equity, $m
  14
  21
  32
  46
  65
  90
  120
  158
  203
  257
  319
  390
  470
  559
  658
  765
  881
  1,006
  1,140
  1,281
  1,431
  1,589
  1,754
  1,927
  2,108
  2,297
  2,493
  2,698
  2,910
  3,131
Total liabilities and equity, $m
  138
  213
  319
  462
  652
  897
  1,204
  1,581
  2,034
  2,569
  3,190
  3,901
  4,701
  5,593
  6,578
  7,651
  8,813
  10,062
  11,397
  12,812
  14,310
  15,887
  17,542
  19,273
  21,083
  22,970
  24,934
  26,979
  29,104
  31,313
Debt-to-equity ratio
  6.500
  7.380
  7.920
  8.260
  8.470
  8.620
  8.710
  8.780
  8.830
  8.870
  8.890
  8.910
  8.930
  8.940
  8.950
  8.950
  8.960
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.980
  8.990
  8.990
  8.990
  8.990
  8.990
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -343
  -529
  -794
  -1,155
  -1,634
  -2,250
  -3,025
  -3,977
  -5,123
  -6,477
  -8,049
  -9,849
  -11,881
  -14,146
  -16,644
  -19,372
  -22,327
  -25,504
  -28,897
  -32,502
  -36,313
  -40,328
  -44,542
  -48,953
  -53,562
  -58,368
  -63,373
  -68,581
  -73,996
  -79,625
Depreciation, amort., depletion, $m
  5
  7
  9
  12
  17
  22
  29
  38
  49
  61
  74
  90
  109
  129
  152
  177
  204
  233
  264
  296
  331
  367
  406
  446
  488
  531
  577
  624
  673
  724
Funds from operations, $m
  -338
  -522
  -785
  -1,143
  -1,617
  -2,228
  -2,995
  -3,939
  -5,074
  -6,416
  -7,975
  -9,759
  -11,772
  -14,017
  -16,492
  -19,195
  -22,123
  -25,271
  -28,634
  -32,206
  -35,983
  -39,960
  -44,136
  -48,508
  -53,074
  -57,836
  -62,796
  -67,957
  -73,323
  -78,901
Change in working capital, $m
  -2
  -3
  -4
  -6
  -8
  -10
  -12
  -15
  -18
  -21
  -25
  -28
  -32
  -35
  -39
  -43
  -46
  -50
  -53
  -56
  -59
  -63
  -66
  -69
  -72
  -75
  -78
  -81
  -84
  -88
Cash from operations, $m
  -336
  -519
  -781
  -1,137
  -1,610
  -2,218
  -2,983
  -3,924
  -5,056
  -6,395
  -7,951
  -9,731
  -11,741
  -13,981
  -16,453
  -19,153
  -22,077
  -25,222
  -28,581
  -32,149
  -35,923
  -39,898
  -44,070
  -48,439
  -53,002
  -57,761
  -62,718
  -67,876
  -73,239
  -78,813
Maintenance CAPEX, $m
  -2
  -3
  -5
  -7
  -11
  -15
  -21
  -28
  -37
  -47
  -59
  -74
  -90
  -109
  -129
  -152
  -177
  -204
  -233
  -264
  -296
  -331
  -367
  -406
  -446
  -488
  -531
  -577
  -624
  -673
New CAPEX, $m
  -10
  -14
  -20
  -27
  -36
  -46
  -58
  -71
  -85
  -100
  -116
  -133
  -150
  -167
  -184
  -201
  -218
  -234
  -250
  -265
  -281
  -295
  -310
  -325
  -339
  -353
  -368
  -383
  -398
  -414
Cash from investing activities, $m
  -12
  -17
  -25
  -34
  -47
  -61
  -79
  -99
  -122
  -147
  -175
  -207
  -240
  -276
  -313
  -353
  -395
  -438
  -483
  -529
  -577
  -626
  -677
  -731
  -785
  -841
  -899
  -960
  -1,022
  -1,087
Free cash flow, $m
  -348
  -537
  -806
  -1,172
  -1,656
  -2,279
  -3,061
  -4,022
  -5,178
  -6,542
  -8,126
  -9,938
  -11,981
  -14,257
  -16,767
  -19,506
  -22,472
  -25,659
  -29,063
  -32,678
  -36,500
  -40,524
  -44,748
  -49,169
  -53,787
  -58,603
  -63,618
  -68,835
  -74,261
  -79,900
Issuance/(repayment) of debt, $m
  30
  68
  95
  129
  171
  220
  276
  339
  408
  482
  559
  639
  721
  803
  885
  966
  1,046
  1,124
  1,200
  1,275
  1,348
  1,419
  1,489
  1,559
  1,628
  1,698
  1,768
  1,840
  1,913
  1,988
Issuance/(repurchase) of shares, $m
  365
  537
  805
  1,170
  1,653
  2,274
  3,055
  4,014
  5,168
  6,531
  8,111
  9,920
  11,961
  14,235
  16,742
  19,480
  22,443
  25,629
  29,031
  32,644
  36,463
  40,485
  44,707
  49,127
  53,743
  58,556
  63,569
  68,785
  74,209
  79,846
Cash from financing (excl. dividends), $m  
  395
  605
  900
  1,299
  1,824
  2,494
  3,331
  4,353
  5,576
  7,013
  8,670
  10,559
  12,682
  15,038
  17,627
  20,446
  23,489
  26,753
  30,231
  33,919
  37,811
  41,904
  46,196
  50,686
  55,371
  60,254
  65,337
  70,625
  76,122
  81,834
Total cash flow (excl. dividends), $m
  47
  67
  94
  127
  168
  216
  270
  332
  398
  470
  544
  622
  701
  781
  861
  940
  1,018
  1,094
  1,168
  1,240
  1,311
  1,380
  1,449
  1,517
  1,584
  1,652
  1,720
  1,790
  1,861
  1,934
Retained Cash Flow (-), $m
  -365
  -537
  -805
  -1,170
  -1,653
  -2,274
  -3,055
  -4,014
  -5,168
  -6,531
  -8,111
  -9,920
  -11,961
  -14,235
  -16,742
  -19,480
  -22,443
  -25,629
  -29,031
  -32,644
  -36,463
  -40,485
  -44,707
  -49,127
  -53,743
  -58,556
  -63,569
  -68,785
  -74,209
  -79,846
Prev. year cash balance distribution, $m
  17
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -301
  -469
  -711
  -1,042
  -1,485
  -2,059
  -2,785
  -3,683
  -4,770
  -6,061
  -7,567
  -9,299
  -11,260
  -13,454
  -15,881
  -18,540
  -21,426
  -24,535
  -27,863
  -31,403
  -35,152
  -39,105
  -43,258
  -47,610
  -52,159
  -56,905
  -61,849
  -66,996
  -72,348
  -77,912
Discount rate, %
  6.50
  6.83
  7.17
  7.52
  7.90
  8.30
  8.71
  9.15
  9.60
  10.08
  10.59
  11.12
  11.67
  12.26
  12.87
  13.51
  14.19
  14.90
  15.64
  16.43
  17.25
  18.11
  19.01
  19.96
  20.96
  22.01
  23.11
  24.27
  25.48
  26.75
PV of cash for distribution, $m
  -283
  -411
  -577
  -780
  -1,015
  -1,276
  -1,552
  -1,829
  -2,090
  -2,319
  -2,501
  -2,624
  -2,680
  -2,666
  -2,584
  -2,440
  -2,246
  -2,014
  -1,761
  -1,500
  -1,244
  -1,005
  -789
  -603
  -448
  -323
  -226
  -153
  -100
  -63
Current shareholders' claim on cash, %
  50.0
  7.2
  1.1
  0.2
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

FINANCIAL RATIOS  of  Neos Therapeutics, Inc. (NEOS)

Valuation Ratios
P/E Ratio -0.2
Price to Sales 2.1
Price to Book -9.4
Price to Tangible Book
Price to Cash Flow -0.3
Price to Free Cash Flow -0.3
Growth Rates
Sales Growth Rate 125%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 300%
Cap. Spend. - 3 Yr. Gr. Rate 14.9%
Financial Strength
Quick Ratio 8
Current Ratio 0.2
LT Debt to Equity -2950%
Total Debt to Equity -3200%
Interest Coverage -27
Management Effectiveness
Return On Assets -78.8%
Ret/ On Assets - 3 Yr. Avg. -51.9%
Return On Total Capital -95.4%
Ret/ On T. Cap. - 3 Yr. Avg. -65.2%
Return On Equity -218.4%
Return On Equity - 3 Yr. Avg. -147.9%
Asset Turnover 0.1
Profitability Ratios
Gross Margin -22.2%
Gross Margin - 3 Yr. Avg. -124.1%
EBITDA Margin -844.4%
EBITDA Margin - 3 Yr. Avg. -1014.8%
Operating Margin -866.7%
Oper. Margin - 3 Yr. Avg. -1105.6%
Pre-Tax Margin -922.2%
Pre-Tax Margin - 3 Yr. Avg. -1265.7%
Net Profit Margin -922.2%
Net Profit Margin - 3 Yr. Avg. -1265.7%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

NEOS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the NEOS stock intrinsic value calculation we used $25 million for the last fiscal year's total revenue generated by Neos Therapeutics, Inc.. The default revenue input number comes from 0001 income statement of Neos Therapeutics, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our NEOS stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6.5%, whose default value for NEOS is calculated based on our internal credit rating of Neos Therapeutics, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Neos Therapeutics, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of NEOS stock the variable cost ratio is equal to 936%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for NEOS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 16.4% for Neos Therapeutics, Inc..

Corporate tax rate of 27% is the nominal tax rate for Neos Therapeutics, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the NEOS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for NEOS are equal to 64.6%.

Life of production assets of 8.1 years is the average useful life of capital assets used in Neos Therapeutics, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for NEOS is equal to -13.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $8.947 million for Neos Therapeutics, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 49.675 million for Neos Therapeutics, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Neos Therapeutics, Inc. at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
JNJ Johnson & John 142.09 107.87  sell
SUPN Supernus Pharm 30.85 180.09  str.buy
LLY Eli Lilly and 115.49 89.42  sell
VRTX Vertex Pharmac 183.97 476.14  str.buy
INVA Innoviva, Inc. 14.20 51.73  str.buy

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.